Abortion Pill Access in Legal Limbo After Latest Court Ruling Sparks Confusion Nationwide

Nationwide access to abortion pills is again in legal limbo, nearly two years after the Supreme Court dismissed a case challenging mail-order prescribing of the widely used drug mifepristone.

Why it matters: A Friday ruling by the 5th U.S. Circuit Court of Appeals dramatically rolled back access to mifepristone, creating confusion for pharmacies, telehealth companies, and clinicians—even in states where abortion remains legal. Some providers have stopped prescribing the drug, others have switched to alternatives, and patients are left uncertain about what comes next.

While the Supreme Court froze the decision on Monday for one week, it could rule as soon as next week that the drug may only be dispensed in person.

Key Developments and Political Fallout

The 5th Circuit’s decision has thrust abortion access into the spotlight during an election year and placed the Trump administration in a difficult political position. The administration has urged courts to pause proceedings until the FDA completes a safety review of mifepristone, which was first approved in 2000. This stance has drawn criticism from anti-abortion advocates who want the administration to invalidate Biden-era policies and reinstate in-person dispensing requirements.

"It's shameful that the Trump administration's inaction has forced pro-life states to take their battle to the federal courts."

Marjorie Dannenfelser, president of SBA Pro-Life America, Friday

Impact on Patients and Providers

The ongoing legal back-and-forth has created "whiplash and chaos" for patients and providers making time-sensitive medical decisions, according to Alexis McGill Johnson, president of Planned Parenthood Action Fund. Brittany Fonteno, CEO of the National Abortion Federation, called Friday’s ruling "the biggest disruption to abortion access since the Dobbs decision overturned Roe v. Wade."

Background of the Legal Battle

The dispute began when Louisiana filed a lawsuit against the FDA, challenging Biden administration rules that expanded access to mifepristone by removing the in-person provider requirement. Federal judges have yet to rule on Louisiana’s underlying legal arguments against the FDA’s rules.

Since Friday’s ruling, the administration has remained largely silent. White House and Department of Health and Human Services spokespeople did not respond to requests for comment on Monday. The administration’s failure to more actively defend the FDA’s rules contributed to the circuit court’s decision to halt teleprescribing, said Katie Keith, director of the Center for Health Policy and the Law at Georgetown University’s O'Neill Institute.

How the Ruling Affects Abortion Access

Both supporters and opponents of abortion rights agree that the ability to mail abortion pills into states with abortion bans—after being prescribed via telehealth—has softened the impact of the overturning of Roe v. Wade.

Fonteno of the National Abortion Federation noted that some providers paused teleprescribing of mifepristone following Friday’s ruling. Others, such as Planned Parenthood of Greater New York, temporarily switched to misoprostol for telehealth abortions. While misoprostol is typically used with mifepristone, it can be safely used alone.

Fonteno said Monday’s stay brought "some relief," but given its temporary nature, there is also a "sense of waiting for the other shoe to drop."